probucol has been researched along with Fatty Liver, Nonalcoholic in 5 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol is an antioxidant with a bis-phenol structure." | 7.01 | Research and Progress of Probucol in Nonalcoholic Fatty Liver Disease. ( Chen, KQ; Cheng, L; Guan, MT; Ke, BY; Wang, SZ; Wang, ZB, 2023) |
| "Probucol is an antioxidant with a bis-phenol structure." | 3.01 | Research and Progress of Probucol in Nonalcoholic Fatty Liver Disease. ( Chen, KQ; Cheng, L; Guan, MT; Ke, BY; Wang, SZ; Wang, ZB, 2023) |
| "High-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) poses therapeutic challenges in elderly subjects." | 1.48 | Bioactive Peptide Improves Diet-Induced Hepatic Fat Deposition and Hepatocyte Proinflammatory Response in SAMP8 Ageing Mice. ( Dumeus, S; Huang, CY; Kuo, WW; Lai, CH; Lin, WT; Lin, YM; Shen, CY; Shibu, MA; Viswanadha, VP; Wang, MF, 2018) |
| "Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression." | 1.40 | [Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism]. ( Gao, J; Liu, B; Wu, R; Wu, X; Xiao, X; Zhang, W; Zhang, X, 2014) |
| "Lipid metabolism and steatohepatitis were assessed." | 1.39 | Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets. ( Gao, J; Liu, B; Wu, R; Wu, XL; Xiao, XQ; Zhang, F; Zhang, W; Zhang, X; Zhou, HM, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, KQ | 1 |
| Ke, BY | 1 |
| Cheng, L | 1 |
| Guan, MT | 1 |
| Wang, ZB | 1 |
| Wang, SZ | 1 |
| Dumeus, S | 1 |
| Shibu, MA | 1 |
| Lin, WT | 1 |
| Wang, MF | 1 |
| Lai, CH | 1 |
| Shen, CY | 1 |
| Lin, YM | 1 |
| Viswanadha, VP | 1 |
| Kuo, WW | 1 |
| Huang, CY | 1 |
| Wu, R | 2 |
| Wu, X | 1 |
| Liu, B | 2 |
| Zhang, W | 2 |
| Gao, J | 2 |
| Xiao, X | 1 |
| Zhang, X | 2 |
| Chen, Y | 1 |
| Pandiri, I | 1 |
| Joe, Y | 1 |
| Kim, HJ | 1 |
| Kim, SK | 1 |
| Park, J | 1 |
| Ryu, J | 1 |
| Cho, GJ | 1 |
| Park, JW | 1 |
| Ryter, SW | 1 |
| Chung, HT | 1 |
| Xiao, XQ | 1 |
| Zhang, F | 1 |
| Zhou, HM | 1 |
| Wu, XL | 1 |
1 review available for probucol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Research and Progress of Probucol in Nonalcoholic Fatty Liver Disease.
Topics: Antioxidants; Cholesterol; Humans; Liver; Non-alcoholic Fatty Liver Disease; Probucol | 2023 |
4 other studies available for probucol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Bioactive Peptide Improves Diet-Induced Hepatic Fat Deposition and Hepatocyte Proinflammatory Response in SAMP8 Ageing Mice.
Topics: Aging; Amino Acid Sequence; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Forkhead Box Pro | 2018 |
[Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism].
Topics: Animals; Anticholesteremic Agents; Diet, High-Fat; Disease Models, Animal; Male; Non-alcoholic Fatty | 2014 |
Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Cells, Cultured; Cilostazol; Disease Models | 2016 |
Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets.
Topics: Animals; Anticholesteremic Agents; Dietary Fats; Fatty Liver; Gene Expression Regulation; Lipid Meta | 2013 |